Clinical Foundations and Management of Restless Legs Syndrome

General Introduction to RLS

Quiz Questions:

A patient diagnosed with RLS has a laboratory profile showing normal serum iron and hemoglobin levels. Which statement best explains why iron therapy might still be considered?

a. Normal serum iron levels indicate that iron transport to the brain is functioning properly.

b. Systemic iron levels are irrelevant because RLS is exclusively a dopaminergic disorder.

c. The patient likely has reduced iron levels specifically within the substantia nigra of the brain.

Explanation: Current research indicates that RLS involves central nervous system iron deficiency and altered brain iron transport, regardless of peripheral serum levels.

d. RLS is primarily a disorder of systemic anemia rather than local deficiency.

Why do the updated AASM guidelines suggest a paradigm shift away from the chronic use of dopaminergic agents for RLS?

a. Dopamine agonists have no initial effect on RLS symptoms.

b. There is a significant risk of symptom augmentation with long-term use.

Explanation: Augmentation risk is the primary driver for choosing safer long-term therapies like gabapentinoids

c. Dopaminergic agents are known to cause severe iron depletion over time.

d. These medications are only effective for primary RLS, not secondary RLS.

Based on the diagnostic criteria, which clinical feature is essential for a diagnosis of RLS?

a. An urge to move legs that is relieved or improved by movement.

Explanation: Relief with movement and the urge to move are core diagnostic requirements.

b. The presence of daytime sleepiness in the majority of cases.

c. Symptoms that are most severe during physical activity.

d. Symptoms that consistently peak in the early morning hours.

Which of the following is categorized as a first-line pharmacologic treatment for adults with RLS according to the strong recommendations in the updated guidelines?

a. Peroneal nerve stimulation devices

b. Low-dose extended-release opioids

c. Diphenhydramine or other antihistamines

d. Gabapentin enacarbil

Explanation: Gabapentinoids, including gabapentin enacarbil, are now the primary recommended first-line therapies.

 

According to the AASM 2025 guidelines, which of these medication classes is now given a “Strong for” recommendation for the treatment of RLS in adults?

a. Opioids

Benzodiazepines

c. Dopamine agonists

d. Gabapentinoids

Explanation: This class, including gabapentin enacarbil, met clinical significance thresholds for disease severity and sleep quality with a favorable long-term safety profile.

When preparing for serum iron studies to evaluate RLS, which protocol should the patient follow to ensure accurate results?

a. Maintain a high-iron diet for three days prior to testing to assess maximum absorption capacity.

b. Take a standard dose of Vitamin C immediately before the test to stabilize serum ferritin levels.

c. Avoid iron-containing foods and supplements for at least 24 hours and test in the morning.

Explanation: This protocol minimizes dietary interference and accounts for the diurnal variation of iron levels in the blood.

d. Fast for 12 hours and schedule the blood draw for the late evening when RLS symptoms are peak.

What is the primary reason for the AASM Task Force moving Dopamine Agonists (DAs) to a “Conditional Against” recommendation?

a. The cost of manufacturing DAs has become prohibitive compared to newer gabapentinoids.

b. Extended use frequently leads to a significant worsening of symptoms known as augmentation.

Explanation: Clinical experience and research confirmed that long-term DA use often makes RLS symptoms more severe and start earlier in the day.

c. DAs cause a high rate of study withdrawal due to immediate allergic reactions.

d. DAs were found to have no short-term efficacy compared to placebo in the meta-analysis.

What are the recommended laboratory thresholds for initiating IV Ferric Carboxymaltose in an adult with RLS?

a. Ferritin < 100 ng/mL and Transferrin saturation < 20%

Explanation: The specific biochemical markers indicate a level of iron deficiency where IV ferric carboxymaltose has shown significant clinical benefit.

b. Ferritin < 50 ng/mL and Transferrin saturation < 15%

c. Ferritin < 200 ng/mL regardless of Transferrin saturation percentage

d. Ferritin < 75 ng/mL and Transferrin saturation < 20%

What is the primary mechanism of action for alpha-2-delta ligands in the treatment of RLS?

a. Inhibition of dopamine reuptake to increase synaptic dopamine levels.

b. Direct agonism of GABA receptors to increase inhibitory signaling.

c. Antagonism of glutamate receptors at the post-synaptic membrane.

d. Selective, high affinity binding to the alpha-2-delta subtype-1 protein to modulate calcium influx

Explanation: By binding to this specific protein, the drugs decrease the influx of calcium at nerve terminals, which subsequently reduces the release of excitatory neurotransmitters like glutamate.

According to the findings by Allen, et al. (2013), how does thalamic glutamate activity relate to sleep disturbances in RLS?

a. There is no significant relationship between thalamic Clx/Cr rations and objective sleep measures.

b. Increased right thalamic glutamate levels are positively correlated with higher wake time after sleep onset (WASO).

Explanation: The data shows a significant correlation (r = 0.61, p = 0.007) where higher glutamate levels in the thalamus are associated with more minutes spent awake during the night.

c. Elevated glutamate levels are specifically lined to an increase in Slow Wave Sleep (SWS).

d. Decreased glutamate levels in the thalamus lead to a higher arousal index.

What does the research suggest regarding the “order of treatments” when using alpha-2-delta ligands and dopamine agonists (DAs)?

a. The sequence of treatment has no impact on the long-term efficacy of either drug class.

b. Initial treatment with dopamine agonists may reduce the subsequent therapeutic response to alpha-2-delta ligands.

Explanation: Data indicates that patients who have previously been treated with DAs show less improvements on alpha-2-delta ligands compared to those who are DA-naive

c. Dopamine agonists should always be used first to prime the receptors for alpha-2-delta ligands.

d. Starting with alpha-2-delta ligands prevents dopamine agonists from being effective later.

Which of the following is a documented advantage of alpha-2-delta ligands over dopamine agonists for long-term RLS management?

a. Greater reduction in periodic limb movements (PLMs) in the short term.

b. Superior reduction in headache and nausea compare to pramipexole.

c. A complete absence of side effects like dizziness and somnolence.

d. A significantly lower incidence rate of augmentation over time.

Explanation: One of the primary reasons to use alpha-2-delta ligands is that they do not care the high risk of treatment-induced worsening (augmentation) seen with dopamine agonists.

What is the primary physiological role of iron in the substantia nigra regarding the development of RLS?

a. It inhibits the activation of the HIF pathways in the brain.

b. It serves as a primary structural component of the blood-brain barrier.

c. It regulates the degradation of melatonin in the choroid plexus.

d. It acts as a co-factor for dopamine (DA) synthesis.

Explanation: Iron is essential for the function of enzymes involved in the production of dopamine, a neurotransmitter critical for motor control.

To ensure an accurate assessment of a patient’s iron stores, what protocol is recommended for measuring serum ferritin and transferrin saturation?

a. Take a sample in the late evening when RLS symptoms are most severe.

b. Administer an oral iron dose one hour before testing to check absorption efficiency.

c. Take a morning sample and avoid iron-containing food or supplements for at least 24 hours prior.

Explanation: A morning sample combined with a period of restriction from iron intake minimizes the risk of transiently elevated serum levels from diet.

d. Measure levels only after a high-protein meal to ensure maximal transport proteins.

According to the AASM 2025 guidelines, which IV iron formulation is assigned a “Strong for” recommendation for the treatment of RLS?

a. Ferumoxytol

b. Ferrous sulphate

c. LMW iron dextran

d. Ferric carboxymaltose

Explanation: This formulation is highlighted for its effectiveness in improving RLS severity, sleep quality, and overall quality of life.

Why is intravenous iron often preferred over oral iron when a patient’s serum ferritin is between 75 – 100 ng/mL?

a. Oral iron cannot cross the blood-brain barrier regardless of concentration.

b. Oral iron only affects peripheral stores and does not reach the substantia nigra.

c. The gating of iron absorption in the gut depends on current iron stores.

Explanation: High iron stores can trigger the body’s natural gating mechanisms, such as hepcidin induction, which blocks the absorption of oral iron.

d. Oral iron formulations like ferrous sulphate are only available by prescription.

According to the guidelines, which is it most appropriate to consider low-dose opioid therapy for a patient with RLS?

a. As a primary treatment specifically for patients who prefer pills over intravenous iron infusions.

b. When a patient experiences mild RLS symptoms that occur fewer than two nights per week.

c. Only after the failure or intolerance of first-line approaches like gabapentinoids or iron replenishment.

Explanation: Opioids should be considered when there is an inadequate benefit, loss of response, or intolerance to first-line approaches.

d. Immediately upon diagnosis for patients with severe symptoms to ensure rapid relief.

For a patient specifically prescribed methadone for refractory RLS, which clinical monitoring step is emphasized?

a. Measuring serum creatinine levels every 4 months to assess renal clearance.

b. Performing a baseline and follow-up assessment of the QTc interval.

Explanation: Checking QTc on everyone on methadone is a necessary monitoring step.

c. Requiring a daily urine toxicology screen for the first month of therapy.

d. Conducting monthly liver function tests to monitor for drug-induced hepatotoxicity.

What does the 5-year data from the National RLS Opioid Registry suggest regarding dosage stability in patients using low-dose opioids?

a. Dosage stability was only achieved when opioids were combined with high-dose dopamine agonists.

b. The majority of patients require a large increase in dosage, exceeding an additional 50 MME.

c. Nearly all patients were able to completely taper off opioids within the first 2 years of the study.

d. Most patients (approximately 66%) maintained stable doses with little to no change in MME.

Explanation: The data indicates that long-term sustained benefit at stable doses is the rule, with 66.1% showing no/little change.

What is the recommended procedural step when transitioning a patient from a dopamine agonist (DA) to an opioid due to augmentation?

a. Replace the dopamine agonist with a high-dose gabapentinoid for one month before introducing any opioid.

b. Taper the dopamine agonist to half-dose first, then introduce the opioid only if symptoms remain severe.

c. Abruptly stop the dopamine agonist and wait for “washout” before starting the opioid.

d. Add the opioid first to establish symptom control, then gradually taper the dopamine agonist over several months.

Explanation: The protocol suggests adding the opioid to gain control before slowly reducing the DA over a period of 3 to 12 months.

A patient with RLS reports that their symptoms have become more severe after their dose of dopamine agonist was increased. What clinical phenomenon is most likely occurring?

a. Tolerance

b. Augmentation

Explanation: Augmentation is characterized by a paradoxical response where symptoms increase in severity with higher doses and improve following a decrease in medication.

c. Natural progression

d. End-of-dose rebound

According to the differential diagnosis table provided, which of the following features is unique to augmentation and is NOT observed in end-of-dose rebound, natural progression, or tolerance?

a. Symptoms spreading to the arms

b. Earlier onset of symptoms

c. Breakthrough symptoms at night

d. Worsening with an increased dose

Explanation: This specific paradoxical reaction is a hallmark of augmentation and dose not occur in natural progression, tolerance, or rebound.

In the management algorithm for severe augmentation, if a 10-day washout period is implemented and symptoms continue to persist, which pharmacological intervention is recommended?

a. Increasing the current dopaminergic dose above the maximum

b. Administration of valerian or valproic acid

c. Introduction of a short-acting dopamine agonist

d. Introduction of an alpha-2-delta ligand or an opioid

Explanation: The guidelines suggest introducing these classes if symptoms remain after a washout or if other switching strategies fail.

According to the study by Allen and Earley (1996), what was the observed rate of augmentation in patients treated with carbidopa/levodopa?

a. 32%

b. 2.7%

c. 82%

Explanation: The study found that carbidopa/levodopa treatment resulted in a very high rate of dose-related augmentation in the majority of patients.

d. 8%

According to the model presented, what defines the baseline dopaminergic state in the brains of RLS patients prior to chronic medication use?

a. A hypodopaminergic pre-synaptic state and a hyperdopaminergic post-synaptic state

b. Increased dopamine transport (DAT) activity leading to excessive synaptic clearance

c. Global depletion of dopamine synthesis combined with an increase in D2 receptor density.

d. A hyperdopaminergic pre-synaptic state and a hypodopaminergic post-synaptic state.

Explanation: Research indicates that while there is increased dopamine synthesis and synaptic release (pre-synaptic), there is a compensatory or pathological decrease in receptor signaling (post-synaptic).

Given that iron is a cofactor for tyrosine hydroxylase (TH), what paradoxical finding was observed in the autopsy tissue of RLS patients?

a. An increase in TH and phosphorylated TH (pTH) protein levels.

Explanation: Despite brain iron insufficiency, the body appears to increase the amount of the rate-limiting enzyme TH in regions like the putamen.

b. A significant decrease in cerebrospinal fluid tetryhydrobiopterin.

c. A reduction in synaptic homovanillic acid (HVA) levels.

d. A total loss of TH protein due to the lack of available iron cofactors.

What is the primary clinical objective and expected outcome of the “drug withdrawal” or “detox” period for patients with augmentation.

a. Restoring natural dopamine levels and desensitizing dopamine receptors after an initial symptom rebound.

Explanation: The goal is to allow the system to return to its baseline function, which ultimately improves symptoms compared to the peak severity of the withdrawal period.

b. Inducing a permanent hyperdopaminergic state to override the need for further medication.

c. Eliminating all RLS symptoms within the first 48 hours of the medication-free period.

d. Immediately transitioning the patient to a higher dose of a different dopamine agonist to prevent rebound.

Which classes of treatment are preferred for avoiding the risk of augmentation?

a. Alpha-2-delta ligands and opioids

Explanation: These classes do not demonstrate the severe rebound or augmentation seen with dopaminergic agents, through tramadol is a noted exception among opioids.

b. Benzodiazepines and dopamine precursors like levodopa

c. Selective serotonin reuptake inhibitors and tramadol

d. Dopamine agonists and iron chelators.

Which factor has been shown to negatively correlate with the presence and severity of RLS during pregnancy?

a. Increased estrogen levels

b. High blood pressure

c. Ferritin levels

Explanation: Lower ferritin levels are associated with both a higher presence of RLS symptoms and greater symptom severity during pregnancy. Ferritin reflects the body’s iron stores, which play an important role in RLS.

d. Maternal age

Which of the following is considered a strong recommendation for managing RLS during pregnancy?

a. Pramipexole therapy

b. Avoidance of aggravating factors

Explanation: Avoidance of aggravating factors is recommended as the first step in managing RLS during pregnancy because it is safe and may help reduce symptoms without medication-related risks.

c. Oxycodone in the first trimester

d. Pregabalin use

Why is zolpidem generally used cautiously during pregnancy?

a. It is ineffective for sleep disorders

b. It increases ferritin levels

c. It may cause adverse maternal-fetal outcomes such as preterm delivery

Explanation: Although zolpidem is not considered teratogenic, it may still contribute to adverse maternal-fetal outcomes, including preterm delivery, so caution is advised during pregnancy.

d. It always causes teratogenic effects

Which non-pharmacologic intervention demonstrated beneficial effects on RLS symptoms and sleep quality during pregnancy?

a. Bed rest throughout pregnancy

b. Progressive muscle relaxation exercises

Explanation: Regular progressive muscle relaxation exercises performed earlier in the day improved RLS symptom intensity, sleep quality, and quality of life during pregnancy.

c. High-dose vitamin C supplementation

d. Sleep restriction therapy

Which statement best describes how pediatric RLS should be diagnosed?

a. Diagnosis is based only on age-specific criteria

b. Diagnosis depends on language and cognitive development rather than age alone

Explanation: Children should describe RLS symptoms in their own words, and that language and cognitive development – not chronological age alone – determine whether diagnostic criteria can be appropriately applied.

c. Diagnosis requires MRI confirmation

d. Diagnosis can only be made if symptoms occur during the daytime

Which of the following is considered a supportive feature for diagnosing pediatric RLS?

a. Frequent headaches

b. Family history of RLS in first-degree relatives

Explanation: A family history of RLS among first-degree relatives is considered a supportive diagnostic feature because early-onset RLs is highly familial and often clusters within families.

c. Elevated blood glucose levels

d. Daytime fever

Which comorbidity is commonly associated with pediatric RLS?

a. Asthma

b. ADHD

Explanation: Approximately 25% of children with RLS also have ADHD, and RLS symptoms may overlap with hyperactivity, impulsivity, and attention difficulties

c. Epilepsy

d. Migraine

What is a key treatment recommendation for pediatric RLS when ferritin levels are low?

a. Immediate surgery

b. Strict bed rest

c. Iron supplementation

Explanation: Evaluating iron status is a high importance. Iron supplementation is recommended when ferritin levels are below 50 ng/mL, since brain iron deficiency is considered a central mechanism in pediatric RLS.

d. Elimination of all physical activity

What does TOMAC therapy stand for in the treatment of RLS?

a. Targeted Oscillating Muscle Activation Control

b. Tonic Motor Activation

Explanation: TOMAC stands for Tonic Motor Activation. The therapy delivers high-frequency electrical stimulation to the peroneal nerves to mimic voluntary leg movements and help suppress RLS symptoms.

c. Therapeutic Orthopedic Motion Assistance Circuit

d. Transcutaneous Oscillating Magnetic Activity Control

TOMAC therapy received which type of recommendation in the 2025 AASM guidelines for adults with RLS?

a. Strong recommendation against use

b. No recommendation due to lack of evidence

c. Conditional recommendation for use

Explanation: The AASM guidelines suggested the use of bilateral high-frequency peroneal nerve stimulation (TOMAC) for adults with RLS as a condition recommendation based on low-certainty evidence.

d. Emergency-only recommendation

For which patient population was TOMAC therapy cleared by the FDA in 2023?

a. Children with mild RLS

b. Pregnant patients with insomnia

c. Patients with occasional muscle cramps

d. Adults with moderate-to-severe medication-refractory RLS

Explanation: TOMAC therapy was FDA-cleared in 2023 specifically for adults with moderate-to-severe RLS that has not responded adequately to medication treatment.

Which adverse event was most commonly associated with TOMAC therapy in clinical studies?

a. Severe cardiac complications

b. Skin discoloration

c. Mild discomfort at the stimulation site

Explanation: Meta-analysis data shows that the most commonly reported device-related adverse event was mild discomfort associated with stimulation, while serious adverse events were rare.

d. Permanent nerve injury